Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360524 | 0.93 | TP53 (0.36) | NR1I3SMN1; SMN2MAPTTP53POLB | |
| SCHEMBL1359897 | 0.91 | MAPT (0.42) | NR1I3SMN1; SMN2MAPTTP53POLB | |
| SCHEMBL12140554 | 0.88 | NR1I3 (0.40) | NR1I3SMN1; SMN2HSP90AA1MAPTTP53 | |
| SCHEMBL1359908 | 0.87 | ALDH1A1 (0.39) | SMN1; SMN2MAPTTP53POLBLMNA | |
| SCHEMBL1361748 | 0.83 | NR1I3 (0.42) | NR1I3SMN1; SMN2HSP90AA1MAPTSCD | |
| SCHEMBL1150754 | 0.83 | ALDH1A1 (0.34) | NR1I3SMN1; SMN2HSP90AA1MAPTCYP11B1 | |
| SCHEMBL12140420 | 0.81 | MAPT (0.35) | NR1I3SMN1; SMN2HSP90AA1MAPTTP53 | |
| SCHEMBL1150443 | 0.76 | ALDH1A1 (0.33) | SMN1; SMN2CYP11B1CYP11B2LMNA | |
| SCHEMBL12862028 | 0.76 | KMT2A (0.36) | SMN1; SMN2HSP90AA1MAPTPOLBSCD | |
| SCHEMBL1150735 | 0.76 | KMT2A (0.36) | SMN1; SMN2HSP90AA1MAPTPOLBSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| EP-2247601-B1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | TPMT, CYP2C19, CYP3A5 | NR1I3 1003/4885SMN1; SMN2 1592/4885HSP90AA1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.